LENZ Therapeutics reports $194M cash as of March 31; holds Commercial Day for LNZ100 launch preparations

LENZ Therapeutics, Inc.

Unaudited cash, cash equivalents and marketable securities approximately $194 million as of March 31, 2025.
Hosting Commercial Day on April 15, 2025, focusing on potential approval and launch of LNZ100.
Presentation includes commercialization strategies, supply chain readiness, and KOL perspectives.
Cash figure is preliminary and subject to completion of financial closing procedures.
No other financial results or guidance were provided in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.